Rapamycin (sirolimus)

The human research tests a narrower set of outcomes than the broad promise of slower aging. It is worth inspecting the main comparisons, subgroup findings and safety together.

A change in a laboratory marker, a test score and everyday function are different outcomes. A statistically detectable result does not by itself tell us whether someone would notice a worthwhile difference.

Check the measured endpoint, comparison and study population. The full profile preserves effect estimates and the source's clinical-significance assessment, including when that assessment is not supplied.

The claim to test: Rapamycin has been shown to slow aging in healthy people.

What the reviewed records say:

The gap: A secondary or subgroup result cannot replace the primary comparison or establish broad healthy-aging benefit.

Durability, effects in other populations and healthy-lifespan outcomes need their own evidence.

Independent replication, meaningful human outcomes, longer follow-up and better safety reporting would make these results easier to interpret.

A secondary or subgroup result cannot replace the primary comparison or establish broad healthy-aging benefit.